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Abstract:  Malignant  renal  carcinoma,  manifest  in  morbid  ageing  rats,  is  the  striking 
component  of  an  otherwise  silent  response  after  about  nine  months  of  exposure  to 
ochratoxin A in the first year of life (daily intake ~100–250 µ g/kg body weight). Reasons 
for  the  long  latency  are  unclear,  as  is  whether  there  would  be  a  similar  carcinogenic 
response if toxin exposure started at one year of age. Therefore, 24 male Fischer rats were 
given 100 µ g ochratoxin A as a daily dietary contaminant for 35 weeks from age 50 weeks. 
Plasma ochratoxin A concentration reached a maximum value of ~8 µ g/mL within one 
month of starting the toxin regimen. No renal carcinomas occurred. Four renal adenomas, 
two  of  which  were  only  microscopic,  were  found  among  the  six  rats  surviving  for  
110 weeks. The findings raise new questions about a difference between young adults and 
mature  adults  in  sensitivity  of  male  rats  to  the  ochratoxin  A-induced  DNA  damage 
necessary for renal carcinogenesis. A pilot histological study of perfuse-fixed brains of the 
toxin-treated rats showed no gross abnormalities, correlating with the consistent absence of 
behavioral or neurological disorders from chronic ochratoxin A exposure regimens in the 
range 100–250 µ g/kg/day during the second half of life. Reasoned questioning concerning 
ochratoxin A as a neurotoxic mycotoxin is made.  
Keywords: adenoma; carcinoma; leukemia; renal tumor pathology; latency; neurotoxicity; 
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1. Introduction 
The extensive National Toxicity Program (NTP) toxicological study of ochratoxin A (OTA) in 
Fischer rats [1] has pointed to renal carcinoma as the notable adverse outcome of lifetime exposure via 
oral gavage. A similar regimen was employed subsequently, using Lewis and Dark Agouti rats, and 
confirmed particularly the sensitivity of males [2]. More recently, carcinogenic responses in males 
given  OTA  homogenized  into  feed  has  established  a  dose-response  relationship  for  this  route  of 
administration of chronic exposure [3,4]. Since the period of OTA exposure necessary to put in place 
subsequent development of renal cancer was unknown, the necessary period commencing with young 
adults was measured in Dark Agouti rats [5]. Three months was insufficient and at least six months 
seemed necessary to be carcinogenic. However, complimentary experiments showed that about nine 
months exposure would cause carcinoma in about 20–25% of individuals. This implies that OTA 
exposure during the latter half of a rat’s life may be completely ineffectual for renal carcinogenesis, 
either because it exceeds what is necessary for causing genetic change or because of physiological 
changes as mature adults age. Thus an experiment was designed at least to show whether there is an 
intrinsic difference between the first and second halves of rat life with respect to sensitivity to OTA 
carcinogenicity. As in other recent studies at Imperial College London, opportunity has been taken to 
study tumors in some depth, commencing exposure at one year of age, as opposed to just recording 
incidence.  Measurement  of  outcome  was  complicated,  as  in  the  NTP  study,  by  the  mononuclear 
leukemia typical of Fischer rats, but the findings can be more readily matched to the NTP protocol 
using that strain.  
There  are  several  reports  of  toxic  effects  of  OTA  on  laboratory  rodent  brain.  For  example, 
anatomical differences were seen in cerebral cortex of mice at six weeks of age, born to an animal 
given a rather large single dose of OTA (3 mg/kg body weight, i.p.) on day 10 of gestation [6]. In rats, 
comparing a range of doses given by oral gavage for  four weeks to young or old females, gross 
histological change was noted as vacuolation in cerebellar medulla and ventral parts of the brain-stem, 
increasingly dose-related in the young rats but inversely so in old rats [7]. Authors concluded that 
brain may be a primary toxicity target organ for OTA and that old rats are more sensitive than young 
ones. However, no adverse neurological effects were recorded in the NTP study during two years of 
OTA exposure, and no abnormal rat behavior was evident throughout all recent lifetime OTA rat 
studies at Imperial College London. Thus, pilot histological study of perfuse-fixed brains was added to 
the  present  experiment, necessarily  made  at or  near the stage  of natural  mortality, which  did  not 
significantly alter group survival dynamics while ensuring that brains came from animals in good 
physical condition, alert and well coordinated. 
2. Methods 
2.1. Animal experiment 
Twenty-four  male  F344  (Fischer)  rats  (Harlan)  were  maintained  on  standard  maintenance  diet 
(RM1 (14.4% protein) Special Diet Services, Witham, Essex, UK) until one year of age, Thereafter, 
caged in groups of three, they were fed daily with 20 g each of the same diet, though in powdered form 
into which had been homogenized an aqueous infused suspension of shredded wheat fermented with a Toxins 2010, 2                         
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culture  of  Aspergillus  ochraceus,  exactly  as  previously  described  [3,4].  OTA  content  of  the 
contaminated diet was 5 ppm, requiring dilution of the toxin-rich fermented product [8] by a factor of 
at least 10
3. All feed was consumed each day. Animal welfare was monitored daily and any animal that 
became jaundiced, lost significant weight or became moribund was euthanized.  
Thirty-five weeks after OTA exposure commenced, a period found to be carcinogenic when applied 
to young rats [3,5,9], nine of the surviving animals ceased OTA exposure while the other 10 continued 
on the contaminated diet for life. Sixteen weeks later, nine of the surviving rats were maintained 
overnight (18 hours) in metabolism cages with food and water ad libitum, for collection of urine into a 
vessel containing 1 mL of a 1% aqueous solution of sodium azide. 
2.2. Urinalysis 
Automated urinalysis for creatinine, protein, calcium, sodium, potassium, urate, urea and phosphate 
was performed in the Chemical Pathology Laboratory at St. Mary’s Hospital, Paddington, London, 
using an Olympus AU640 instrument with methodology described in [10].  
2.3. OTA in blood plasma 
Quantitative  measurement  was  made  at  the  Central  Science  Laboratory,  York  by  validated 
methodology as previously described [11].  
2.4. Brain Histopathology 
Survival of some animals to 115 weeks of age coincided with the age of the formal NTP end-point 
for toxicological studies (105 weeks of experiment commencing with rats of about 10 weeks of age). 
Thus, the opportunity was taken to explore the histological status of brain after a year’s exposure to 
OTA as mature adults, but while animals yet showed no clinical morbidity.  
Six  rats  were  anaesthetized  with  fluothane/oxygen,  further sedated with  pentobarbitone sodium  
(100 mg, i.p.), and killed by transcardiac perfusion, following a brief flush of physiological saline, 
with formalin-acetic acid solution (10%:2%) in distilled water at a pressure of 100–120 mm Hg for  
12 min. Heads were submerged in the same fixative for three hours before dissection. Whole brains 
were stored in 4% formalin at 4 ° C. Subsequently, the brains from two rats treated continuously with 
OTA, and from one which ceased OTA treatment after 35 weeks, were selected for histological study; 
brains were divided along saggital and coronal aspects (Figure 1), and tissues embedded in wax blocks 
employing chloroform as the clearing solvent. Sections (10 µ m) were stained with hematoxylin and 
eosin in the Breast Pathology laboratory, Guy’s Hospital, London.  
2.5. General histology  
Standard wax-embedded blocks were also prepared from kidneys and testes, and sections (3–4 µ m) 
were stained with hematoxylin and eosin also at Guy’s Hospital.  Toxins 2010, 2                         
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Figure 1. Brain sectioning for histology. 
 
3. Results 
Rats maintained body weight throughout the 35 weeks of exposure to OTA and beyond (Figure 2). 
Figure 2. Mean body weight from 25 weeks before OTA treatment commenced until the 
105 week stage. Undulations after 50 weeks reflect premature death of some individuals 
(c.f. Figure 4), but a steady value was generally maintained. 
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Plasma OTA concentration reached a steady state value of ~8 µg/mL within one month of transfer 
to the contaminated diet (Figure 3). End stage concentration measured in some rats at least 100 weeks 
old (Table 1) showed lower values attributed to ageing, and elimination to near the limit of detection 
16 weeks after ceasing OTA exposure. 
Plasma OTA concentration reached a steady state value of ~8 µg/mL within one month of transfer 
to the contaminated diet (Figure 3). End stage concentration measured in some rats at least 100 weeks 
old (Table 1) showed lower values attributed to ageing, and elimination to near the limit of detection 
16 weeks after ceasing OTA exposure. 
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Figure  3.  Accumulation  of  OTA  in  blood  plasma  during  the  first  eight  weeks  on 
contaminated diet. 
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Table 1. Plasma OTA concentration measured in blood from six rats at necropsy. 
Age (weeks) 
OTA continuous 
since 50 weeks old 
OTA ceased 16 weeks previous  
to this blood sample 
100  2.0 µ g/mL   
101  2.5 µ g/mL  
1.8  ng/mL,  consistent  with  ~13 
plasma half lives elapsed since 
OTA exposure ceased. 
109  4.6 µ g/mL   
109  1.1 µ g /mL   
110  0.3 µ g/mL   
110  0.6 µ g/mL   
Fifty-six  weeks  after  OTA  treatment  commenced,  difference  was  found  in  measured  urine 
parameters, between the group which continued OTA treatment for a further 21 weeks (Table 2) and 
the group in which OTA treatment had been discontinued, only in increased excretion of protein in 
some individuals in response to continuing ingestion of OTA. 
Survival dynamics from the start of OTA exposure is shown in Figure 4, annotated with a principal 
feature for each case. Only three of the rats died unexpectedly overnight. The typical mononuclear 
leukemia,  that  potentially  complicates  assessment  of  renal  tumorigenic  response  in  F344  rats  by 
premature need for euthanasia, became evident in nine animals (38%). These were distributed as usual 
across  the  last  quarter  of  life.  However,  careful  scrutiny  of  renal  histology  meant  that  the  first 
decedence  (at  80  weeks)  could  have  been  before  potential  proliferation  of  a  recognizable  renal 
neoplastic lesion attributable to OTA had occurred. Similarly, euthanasia of the cases of lip sarcoma 
and pancreatic tumor at 84 and 85 weeks might have precluded evidence of a late-developing renal 
neoplasm. Later, a testis tumor was found in a rat in each of the groups, whether continuing OTA 
ingestion or discontinued.  Toxins 2010, 2                         
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Table 2. Comparative uro-analytical findings from groups of rats surviving at ~2 years of 
age.  They  had  been  consuming  ochratoxin  A-contaminated  diet  for  35  weeks  from  
50 weeks of age. At 85 weeks of age, one group remained on the OTA diet while the other 
reverted  to  normal  rat  diet.  Ultimate  principal  oncological  findings  are  given  for  each 
animal. Kidney indicates the individuals in which renal adenoma was later found. Units; 
urine  (18  h,  mL),  creatinine  (mmol/L),  protein  (g/L),  other  solutes  (mmol/mmol 
creatinine).  
Prospective 
oncology 
Volume  Calcium  Urate  Creatinine  Protein  Sodium  Potassium  Phosphate  Urea 
Continuous OTA 
Testis  7.6  0.24  0.30  9.75  0.72  3.6  17.53  4.08  76.18 
Testis *  11.7  0.53  0.23  6.14  1.84  9.15  22.65  3.32  77.22 
Testis *   8.0  0.12  0.25  8.35  1.11  6.08  16.17  4.21  68.14 
Kidney  8.1  0.16  0.20  10.77  0.64  6.13  15.69  3.14  67.49 
Testis, 
Leukemia 
12.0  0.36  0.45  5.81  2.25  6.80  16.88  6.12  64.41 
Mean   9.5  0.28  0.29  7.56  1.31  6.35  17.78  4.17  70.69 
OTA ceased for 22 weeks 
Kidney 
(unilateral, 
total; 6.4 g) 
12.4  0.11  0.28  7.84  0.62  5.33  14.54  3.35  56.12 
Testis, 
Leukemia, 
Kidney 
12.0  0.25  0.39  7.73  0.35  6.53  15.39  2.80  61.80 
Testis, 
subcutaneous 
sarcoma 
13.0  0.46  0.28  5.41  0.88  8.17  19.77  4.17  76.11 
Leukemia, 
Kidney * 
10.7  0.57  0.27  8.20  0.87  6.14  16.47  3.33  59.54 
Mean  12.0  0.35  0.31  7.30  0.68  6.54  16.54  3.41  63.39 
* Histology of perfusion-fixed brain studied. 
Correlated with advanced ageing at 110 weeks or more, a focal unilateral renal adenoma was found 
in four rats (Figure 4). All were solid compression tumors within the kidney capsule and without any 
evidence of distant metastasis. The first (rat 1) was small (7  ×  8 mm), distorting the kidney, but 
cellular proliferation internally retaining a tubular arrangement typical of adenoma (Figure 5A). The 
second (rat 2) was larger (16 ×  12 mm, Figure 5B and 5C), preserving the papilla part of the kidney 
(Figure 5D, total tumorous organ weight 6.4 g) but probably destroying excretory function. Tumor 
histology  was  of  typical  adenoma.  The  third  (rat  3)  was  only  detected  microscopically.  It  was 
comprised of only two or three adjacent swollen tubules with regular internal cellular proliferation 
(Figure  5E);  a  central  group  of  necrotic  cells  with  pyknotic  nuclei  is  consistent  with  increasing 
isolation from vasculature as the tumor proliferated in this aged animal. The fourth was in the last 
surviving rat and was a spherical tumor (3 mm) diameter, located centrally, not notably distorting  Toxins 2010, 2                         
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the  kidney,  and  only  detected  during  histological  preparation.  It  was  probably  not  of  current  
clinical significance. 
Figure 4. Survival dynamics annotated with principal outcome for each rat. 
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Figure 5. Renal adenomas. A: rat 1, junction between adenoma and kidney cortex. Note 
the eosinophilic (necrotic) region top left; B: rat 2,  tumorous kidney in situ; C: rat 2, 
excised  tumorous  kidney;  D:  rat  2,  tumorous  kidney  in  section  showing  renal  papilla;  
E: rat 2, typical adenoma histopathology; F: rat 3, micro-adenoma in situ with central 
eosinophilic (necrotic) region. 
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Histology of the three brains showed similar features. Generally there was evidence of swollen 
astrocytes, and "haloes" around neurons throughout the brains, which is probably a fixation/processing 
artifact; this is difficult to avoid even after perfuse-fixation. In both a continuously OTA-treated rat 
and the one treated for the shorter period, there was pronounced swelling around the lateral and third 
ventricles  which  is  probably  also  artifactual,  although  this  was  not  so  prominent  in  the  other 
continuously treated rat. 
Neurons in most regions of all rats appeared fairly normal. However, there were some eosinophilic 
Purkinje neurons in the cerebellum of all animals (Figure 6C). One of the continuously treated animals 
also had eosinophilic neurons in the ventral striatum and dorsal hippocampus (Figure 6B and 6D). The 
somewhat  angular  appearance  of  the  cells,  and  the  lack  of  an  obvious  concomitant  increase  in 
cellularity  (microglial/astrocytic  response)  around  them,  suggests  that  these  appearances  are  also 
artifactual. From experience, Purkinje cells are particularly prone to this. More significant, may be the 
large eosinophilic bodies in the cuneate nucleus (Figure 7), located in the brainstem just below the 
back of the cerebellum. These were present in all animals, and in one of the continuously treated 
animals there was some evidence of them in the fiber tract leading up to the nucleus. 
Figure  6.  Photomicrographs  of  regions  of  perfuse-fixed  brain  of  rat  consuming  
OTA-contaminated diet during weeks 50 to 109 of life. A: hippocampus, normal pyramidal 
neurons, × 20 objective; B: hippocampus, eosinophilic pyramidal neurons, × 20 objective;  
C:  cerebellum,  eosinophilic  Purkinje  cells,  × 20  objective:  D:  striatum,  eosinophilic 
neurons, × 40 objective. 
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Figure  7.  Photomicrograph  of  cuneate  of  perfuse-fixed  brain  of  rat  consuming  OTA-
contaminated  diet  during  weeks  50  to  109  of  life,  illustration  of  eosinophilic  bodies  
(× 40 objective). 
 
4. Discussion 
Throughout the study, exposure to OTA as a dietary contaminant was well tolerated as indicated by 
rat body weight, urinalysis and survival, which were not notably different from the control (untreated) 
groups already described for concurrent lifetime studies [3,4]. Maximum plasma OTA concentration 
was similar to that achieved in [3] and which caused metastasizing renal carcinomas. Further, the 
kinetics of plasma OTA accumulation during the first month of OTA exposure followed the pattern 
predicted from classical pharmacokinetic study also in Fischer male rats [12]. In the present context, 
where development of several cases of renal carcinoma could reasonably have been expected in a 
study not shortened for all rats to the standard two years of NTP studies, it is therefore notable that 
carcinoma  did  not  occur.  The  findings  at  least  demonstrate  the  value  of  long  term  whole  animal 
experiments in assessing the real toxicological significance of OTA, which is much more difficult to 
perceive either from acute animal studies or from experiments on tissue-cultured cells. 
Unlike in other studies, in which exposure to feed contaminated with OTA commenced in young 
rats [3–5,9] but after which there was a latency period of many months before renal tumors were 
found, the present protocol allowed much less opportunity for expression of long latency. Nevertheless 
if,  as  recently  reported  [9],  about  35  weeks  of  OTA  exposure  was  sufficient  for  unilateral  renal 
tumorigenesis to be put in place, the first adenoma here was only found after a further six months of 
continuous  OTA  exposure,  at  an  age  close  to  the  normal  endpoint  of  NTP  toxicological  studies. 
Notably the other three small adenomas all occurred in rats given only the basic 35 weeks of OTA 
exposure, but found at an age beyond a classical two year endpoint. 
The present findings raise questions about the mechanism and kinetics of OTA renal tumorigenesis 
and  its  components  of  promotion,  adenoma  proliferation  and  aneuploidization,  and  transition  to 
infiltrative malignant carcinoma with potential for distant metastasis. At least part of the mechanism 
seems to involve direct covalent interaction with DNA [13]. 
It is now nearly half a century since OTA was discovered. Although a potent renal carcinogen in the 
male rat, its significance for human health remains obscure. It is thus the more urgent to determine 
whether the rat is a valid experimental model for any human carcinoma. Toxins 2010, 2                         
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The eosinophilic bodies in cuneate nuclei of brainstems seem to be real changes, although they do 
not appear to have stimulated a cellular reaction. They are reminiscent of dystrophic fiber terminals 
found in the gracile and cuneate tracts/nuclei of three month old mice treated with organophosphorous 
compounds.  Such  swellings  occurred  in  control  mice,  but  less  frequently  than  in  dosed  animals. 
However, the present observations are likely to be of ageing-related changes in the present very old 
male rats. Further histopathological study of these brains, and others from the present experiment (all 
are  available on request),  might include labeling  of sections  for GFAP and  neurofilaments  to aid 
interpretation  of  the  swellings.  It  is  concluded  that  none  of  the  minor  histological  features  could 
reasonably  be  attributed  other  than  to  ageing and/or  tissue processing.  There was no evidence of 
adverse neurohistopathological effect of continuing the dietary OTA exposure for a further five months 
during ageing; histology in Figure 6 is of a non-leukemic rat given OTA for a total of 59 weeks.  
In contrast, a distribution study [14] tracing OTA (0.4 µ g) given by injection into a lateral ventricle, 
none was distributed to cerebellum, striatum or ventral mesencephalon and none was transferred to 
blood. Also, OTA was given by oral gavage (289 µ g/kg/day) for eight days to pre-pubertal male rats. 
Of the proportion then found in brain (not stated), one-third was in the cerebellum but only 3%–5% 
was each in the striatum, hippocampus and ventral mesencephalon. Consequently, authors designated 
these regions as the main OTA targets in ‘adult’ rat brain. Unfortunately, OTA concentration was not 
measured  in  the  blood  after  chronic  OTA  administration,  but  from  the  present  study  it  might  be 
estimated at 2–3 µ g/mL. Since brain vasculature had not been flushed prior to further analysis, the 
small amounts of OTA measured in brain structures may be attributed to OTA in brain vasculature. 
Claims of OTA accumulation in kidney can be subject to similar misinterpretation [13]. 
Another acute (i.p.) study in mice [15] found DNA damage, DNA repair and oxidative stress across 
six brain regions, but only at rather high OTA dose. That study was extended to question involvement 
of low dose exposure in parkinsonism [16]; however, biologically-active dose vastly exceeds that of 
natural human intake. 
Aggregating brain cell culture, as an in vitro model for neurotoxicological study, has been applied 
to  OTA  for  investigating  gene  expression  mechanisms  underlying  neurotoxicity  [17].  The  elegant 
technique allowed intimate contact between aggregates and OTA in a nutrient medium and observed 
changes related to brain inflammatory response. Such might be significant in vivo if OTA has access to 
developing fetal brain. In contrast, in the present study, OTA circulated bound to serum proteins and 
there is no compelling evidence of significant transfer out of brain vasculature. Unqualified description 
of naturally-occurring OTA as a ‘neurotoxin’ may therefore be misleading.  
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